{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:33:27Z","timestamp":1792150407143,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["glob health res policy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prevention of type 2 diabetes is becoming an urgent public health concern in low and middle-income countries (LMICs). However, there is currently no evidence of a cost-effective approach of health behaviour interventions from community settings in low-income countries like Nepal. Therefore, this study aimed to assess the within-trial economic evaluation of a health behaviour intervention compared with usual care for managing type 2 diabetes in a community setting in Nepal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We randomly assigned 30 clusters comprising 481 patients with type 2 diabetes of which 15 to a health behaviour intervention (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009238 patients) and 15 to the usual care (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009243 patients). Patients in the intervention group received community health workers-led intensive training for diabetes self-management along with regular phone calls and ongoing support from peer supporters. Costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) as costs per QALYs gained were assessed after 6-month from a healthcare system perspective. Probabilistic sensitivity analysis was conducted using 10,000 Monte Carlo simulations to assess the impact of uncertainty of cost-effectiveness analysis under the threshold of three times gross domestic product (GDP) per capita for Nepal (i.e., US $4,140).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over the 6-month, the intervention yielded an incremental cost of US $28.55 (95% CI\u2009=\u2009US $21.26 to US $35.84) per person and an incremental QALYs of 0.0085 (95% CI\u2009=\u2009-0.0106 to 0.0275) per person. The ICER associated with the health behaviour intervention was US $3,358.82 (95% CI\u2009=\u2009US $-2005.66 to US $3,974.54) per QALY gained, which was below the estimated threshold, indicating a cost-effective approach with a net monetary benefit of US $6.64 (95% CI\u2009=\u2009US $-22.62 to US $78.01). Furthermore, the probabilistic sensitivity analysis consisting of 10,000 Monte Carlo simulations indicates that the intervention being cost-effective at the given threshold was 89.63%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Health behaviour interventions in community settings are a cost-effective approach to manage type 2 diabetes, offering good value for money. However, more studies focused on long-term follow-up across diverse setting of LMICs should be warranted to assess the maximum impact of such interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Australia and New Zealand Clinical Trial Registry (ACTRN12621000531819) Registered on 6\n                      <jats:sup>th<\/jats:sup>\n                      May 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41256-024-00364-z","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T03:16:34Z","timestamp":1734405394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Health economic evaluation alongside randomised clinical trial of a health behaviour intervention to manage type 2 diabetes in Nepal"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-3762","authenticated-orcid":false,"given":"Padam Kanta","family":"Dahal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lal","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashidul Alam","family":"Mahumud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grish","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biraj","family":"Karmacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Sugishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneel","family":"Vandelanotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"issue":"8","key":"364_CR1","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00125-022-05713-6","volume":"65","author":"J Liu","year":"2022","unstructured":"Liu J, Bai R, Chai Z, Cooper ME, Zimmet PZ, Zhang L. Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990\u20132019 data. Diabetologia. 2022;65(8):1339\u201352.","journal-title":"Diabetologia"},{"issue":"2","key":"364_CR2","doi-asserted-by":"publisher","first-page":"e060750","DOI":"10.1136\/bmjopen-2022-060750","volume":"12","author":"N Shrestha","year":"2022","unstructured":"Shrestha N, Karki K, Poudyal A, Aryal KK, Mahato NK, Gautam N, et al. Prevalence of diabetes mellitus and associated risk factors in Nepal: findings from a nationwide population-based survey. BMJ Open. 2022;12(2):e060750.","journal-title":"BMJ Open"},{"key":"364_CR3","volume-title":"IDF diabetes atlas 10th edition","author":"International Diabetes Federation","year":"2021","unstructured":"International Diabetes Federation. IDF diabetes atlas 10th edition. Brussels: International Diabetes Federation; 2021."},{"issue":"10","key":"364_CR4","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.2337\/dc07-0150","volume":"30","author":"A Ramachandran","year":"2007","unstructured":"Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30(10):2548\u201352.","journal-title":"Diabetes Care"},{"issue":"12","key":"364_CR5","doi-asserted-by":"publisher","first-page":"e0242962","DOI":"10.1371\/journal.pone.0242962","volume":"15","author":"W Hu","year":"2020","unstructured":"Hu W, Xu W, Si L, Wang C, Jiang Q, Wang L, et al. Cost-effectiveness of the Da Qing diabetes prevention program: a modelling study. PLoS One. 2020;15(12):e0242962.","journal-title":"PLoS One"},{"issue":"1","key":"364_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12916-020-01704-9","volume":"18","author":"T Sathish","year":"2020","unstructured":"Sathish T, Oldenburg B, Thankappan KR, Absetz P, Shaw JE, Tapp RJ, et al. Cost-effectiveness of a lifestyle intervention in high-risk individuals for diabetes in a low- and middle-income setting: trial-based analysis of the Kerala Diabetes Prevention Program. BMC Med. 2020;18(1):251.","journal-title":"BMC Med"},{"issue":"17","key":"364_CR7","doi-asserted-by":"publisher","first-page":"10799","DOI":"10.3390\/ijerph191710799","volume":"19","author":"PK Dahal","year":"2022","unstructured":"Dahal PK, Rawal LB, Mahumud RA, Paudel G, Sugishita T, Vandelanotte C. Economic evaluation of health behavior interventions to prevent and manage type 2 diabetes mellitus in Asia: a systematic review of randomized controlled trials. Int J Environ Res Public Health. 2022;19(17):10799.","journal-title":"Int J Environ Res Public Health"},{"issue":"19","key":"364_CR8","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.3390\/ijerph191912611","volume":"19","author":"MD Butt","year":"2022","unstructured":"Butt MD, Ong SC, Wahab MU, Rasool MF, Saleem F, Hashmi A, et al. Cost of illness analysis of type 2 diabetes mellitus: the findings from a lower-middle income country. Int J Environ Res Public Health. 2022;19(19):12611.","journal-title":"Int J Environ Res Public Health"},{"key":"364_CR9","doi-asserted-by":"publisher","unstructured":"Afroz A, Alramadan MJ, Hossain MN, Romero L, Alam K, Magliano DJ, Billah B. Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review. BMC Health Serv Res. 2018;18(1):972. https:\/\/doi.org\/10.1186\/s12913-018-3772-8.","DOI":"10.1186\/s12913-018-3772-8"},{"key":"364_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.12688\/f1000research.53970.2","volume":"10","author":"DB Shrestha","year":"2021","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, Marahatta A, Lamichhane S, Nepal S, et al. Type 2 diabetes mellitus in Nepal from 2000 to 2020: a systematic review and meta-analysis. F1000Res. 2021;10:543.","journal-title":"F1000Res"},{"issue":"1","key":"364_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s13063-023-07451-5","volume":"24","author":"L Rawal","year":"2023","unstructured":"Rawal L, Dahal P, Paudel G, Biswas T, Shrestha R, Makaju D, et al. Community-based lifestyle intervention for diabetes (Co-LID study) management in rural Nepal: study protocol for a clustered randomized controlled trial. Trials. 2023;24(1):441.","journal-title":"Trials"},{"key":"364_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fpubh.2019.00345","volume":"7","author":"BM Kwan","year":"2019","unstructured":"Kwan BM, McGinnes HL, Ory MG, Estabrooks PA, Waxmonsky JA, Glasgow RE. RE-AIM in the real world: use of the RE-AIM framework for program planning and evaluation in clinical and community settings. Front Public Health. 2019;7:345.","journal-title":"Front Public Health"},{"issue":"1","key":"364_CR13","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1017\/cts.2021.789","volume":"5","author":"JS Holtrop","year":"2021","unstructured":"Holtrop JS, Estabrooks PA, Gaglio B, Harden SM, Kessler RS, King DK, et al. Understanding and applying the RE-AIM framework: clarifications and resources. J Clin Transl Sci. 2021;5(1):e126.","journal-title":"J Clin Transl Sci"},{"key":"364_CR14","unstructured":"Nepal Telecommunications Authority. Annual reports 2078\/079. In: Authority NT, editor. Kathmandu: Nepal Telecommunications Authority; 2022."},{"key":"364_CR15","unstructured":"Government of Nepal MoPIaT, Department of Transport Management. Vehicle fare. Kathmandu: Government of Nepal; 2022 [updated 2021]. Available from: https:\/\/www.dotm.gov.np\/VehicleFare\/Search. Cited 2022 Febuary 22."},{"key":"364_CR16","unstructured":"Open Knowledge Nepal. Kalimati Tarkari Dataset (fruits and vegetables price). Kathmandu: Open Knowledge Nepal; 2023 [updated January 2023]. Available from: https:\/\/opendatanepal.com\/dataset\/kalimati-tarkari-dataset, https:\/\/kalimatimarket.gov.np\/. Cited 2023 18 Febuary."},{"key":"364_CR17","unstructured":"American Heart Association. Fruits and vegetables serving sizes infographic. United State: American Heart Association; 2022 [updated 2022]. Available from: https:\/\/www.heart.org\/en\/healthy-living\/healthy-eating\/add-color\/fruits-and-vegetables-serving-sizes. Cited 2022 Febuary 27."},{"key":"#cr-split#-364_CR18.1","unstructured":"Government of Nepal Mol, Employement and Social Security. Minimum monthly wages\/salary in Nepal 2078\/2021 set. Nepal: Nepal Government"},{"key":"#cr-split#-364_CR18.2","unstructured":"2021. Available from: https:\/\/drive.google.com\/file\/d\/1bPunPvT6dCml-jOIYtOn5sEaregDeN7h\/view. Cited 2022 25 Febuary."},{"issue":"1","key":"364_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"90001","key":"364_CR20","doi-asserted-by":"publisher","first-page":"26S","DOI":"10.1093\/fampra\/17.suppl_1.S26","volume":"17","author":"M Sculpher","year":"2000","unstructured":"Sculpher M. Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines. Fam Pract. 2000;17(90001):26S \u2013 31.","journal-title":"Fam Pract"},{"key":"364_CR21","unstructured":"The World Bank. Official exchange rate (LCU per US$, peroid average). Washington DC: World Bank; 2022 [updated December 2022]. Available from: https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF?end=2022&start=1960&view=chart. Cited 2023 12 Febuary."},{"issue":"2","key":"364_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","volume":"15","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127\u201337.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"364_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14737167.2020.1779062","volume":"20","author":"AK Lugn\u00e9r","year":"2020","unstructured":"Lugn\u00e9r AK, Krabbe PFM. An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):331\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"364_CR24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jval.2021.11.1370","volume":"25","author":"G Jyani","year":"2022","unstructured":"Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, et al. Development of an EQ-5D value set for India using an extended design (DEVINE) study: the Indian 5-level version EQ-5D value set. Value Health. 2022;25(7):1218\u201326.","journal-title":"Value Health"},{"key":"364_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/B978-0-323-05796-7.00042-4","volume-title":"Clinical nuclear cardiology","author":"LJ Shaw","year":"2010","unstructured":"Shaw LJ. Chapter 24 - Cost-effectiveness of myocardial perfusion single-photon emission computed tomography. In: Zaret BL, Beller GA, editors. Clinical nuclear cardiology. 4th ed. Philadelphia: Mosby; 2010. p. 400\u201312.","edition":"4"},{"key":"364_CR26","unstructured":"International Monetary Fund. GDP per capita, current prices. Washington DC; 2023. [updated Febuary 2023]. Available from: https:\/\/www.imf.org\/external\/datamapper\/NGDPDPC@WEO\/NPL?zoom=NPL&highlight=NPL. Cited 2023 14 August 2023."},{"issue":"4","key":"364_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1017\/S0266462311000365","volume":"27","author":"L Irvine","year":"2011","unstructured":"Irvine L, Barton GR, Gasper AV, Murray N, Clark A, Scarpello T, et al. Cost-effectiveness of a lifestyle intervention in preventing type 2 diabetes. Int J Technol Assess Health Care. 2011;27(4):275\u201382.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"364_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jval.2021.07.013","volume":"25","author":"C Bailey","year":"2022","unstructured":"Bailey C, Skouteris H, Harrison CL, Hill B, Thangaratinam S, Teede H, et al. A comparison of the cost-effectiveness of lifestyle interventions in pregnancy. Value Health. 2022;25(2):194\u2013202.","journal-title":"Value Health"},{"issue":"5","key":"364_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF03261866","volume":"10","author":"LA Polgreen","year":"2012","unstructured":"Polgreen LA, Brooks JM. Estimating incremental costs with skew: a cautionary note. Appl Health Econ Health Policy. 2012;10(5):319\u201329.","journal-title":"Appl Health Econ Health Policy"},{"key":"364_CR30","unstructured":"York Health Economics Consortium; University of York. Net monetary benefit (online). York Health Economics Consortiun; University of York; 2016 [updated 2016]. Available from: https:\/\/yhec.co.uk\/glossary\/net-monetary-benefit\/. Cited 2023 Febuary 19."},{"issue":"5","key":"364_CR31","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1111\/j.1523-1755.2004.00950.x","volume":"66","author":"PA McFarlane","year":"2004","unstructured":"McFarlane PA, Bayoumi AM. Acceptance and rejection: cost-effectiveness and the working nephrologist. Kidney Int. 2004;66(5):1735\u201341.","journal-title":"Kidney Int"},{"key":"364_CR32","doi-asserted-by":"crossref","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. Wiley;\u00a0New York:\u00a01987.","DOI":"10.1002\/9780470316696"},{"key":"364_CR33","doi-asserted-by":"publisher","unstructured":"Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP\/DPPOS. Diabetes Care. 2012;35(4):723\u201330. https:\/\/doi.org\/10.2337\/dc11-1468.","DOI":"10.2337\/dc11-1468"},{"issue":"8","key":"364_CR34","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.2337\/dc09-0363","volume":"32","author":"MA Jacobs-van der Bruggen","year":"2009","unstructured":"Jacobs-van der Bruggen MA, van Baal PH, Hoogenveen RT, Feenstra TL, Briggs AH, Lawson K, et al. Cost-effectiveness of lifestyle modification in diabetic patients. Diabetes Care. 2009;32(8):1453\u20138.","journal-title":"Diabetes Care"},{"issue":"8","key":"364_CR35","doi-asserted-by":"publisher","first-page":"e0220116","DOI":"10.1371\/journal.pone.0220116","volume":"14","author":"S Dineen-Griffin","year":"2019","unstructured":"Dineen-Griffin S, Garcia-Cardenas V, Williams K, Benrimoj SI. Helping patients help themselves: a systematic review of self-management support strategies in primary health care practice. PLoS One. 2019;14(8):e0220116.","journal-title":"PLoS One"},{"issue":"3","key":"364_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/pubmed\/fdp079","volume":"32","author":"DR Rappange","year":"2009","unstructured":"Rappange DR, Brouwer WBF, Rutten FFH, van Baal PHM. Lifestyle intervention: from cost savings to value for money. J Public Health. 2009;32(3):440\u20137.","journal-title":"J Public Health"},{"issue":"Suppl 1","key":"364_CR37","doi-asserted-by":"publisher","first-page":"i56","DOI":"10.1093\/eurpub\/ckac074","volume":"32","author":"A Barbosa","year":"2022","unstructured":"Barbosa A, Whiting S, Ding D, Brito J, Mendes R. Economic evaluation of physical activity interventions for type 2 diabetes management: a systematic review. Eur J Public Health. 2022;32(Suppl 1):i56\u201366.","journal-title":"Eur J Public Health"}],"container-title":["Global Health Research and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41256-024-00364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41256-024-00364-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41256-024-00364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:27:09Z","timestamp":1768404429000},"score":1,"resource":{"primary":{"URL":"https:\/\/ghrp.biomedcentral.com\/articles\/10.1186\/s41256-024-00364-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s41256-024-00364-z","relation":{},"ISSN":["2397-0642"],"issn-type":[{"value":"2397-0642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval for this study was obtained from the Human Research Ethics Committee (HRECs) of Nepal Health Research Council, Nepal (#944\/2019P); Tokyo Women\u2019s Medical University, Japan (IRC-approval 200801); Kathmandu University, Nepal (IRC-KUMS 26\/20); and Central Queensland University, Australia (CQU RSH\/HE 0000022453). This intervention was registered in the Australia and New Zealand Clinical Trial Registry (ANZCTR) (ACTRN12621000531819).All participants provide their informed consent prior to participation. The privacy and confidentiality of each participant\u2019s information gathered and disseminated throughout the data collection process was strictly maintained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PKD is a recipient of Research Training Program Scholarships from by the Australian Government. CV is supported by an Australian Research Council (ARC) Future Fellowship (#FT210100234). None of the funders had any involvement with data collection, data analyses and preparing the manuscript for publication. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}